We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Stock Sinks As Market Gains: Here's Why
Read MoreHide Full Article
Pfizer (PFE - Free Report) ended the recent trading session at $29.45, demonstrating a -1.17% change from the preceding day's closing price. This move lagged the S&P 500's daily gain of 0.28%. Meanwhile, the Dow gained 0.19%, and the Nasdaq, a tech-heavy index, added 0.27%.
Prior to today's trading, shares of the drugmaker had gained 3.76% outpaced the Medical sector's gain of 2.43% and the S&P 500's loss of 0.2%.
Market participants will be closely following the financial results of Pfizer in its upcoming release. The company plans to announce its earnings on November 3, 2026. The company is predicted to post an EPS of $0.72, indicating a 17.24% decline compared to the equivalent quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $16.13 billion, down 3.14% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $2.94 per share and a revenue of $62.48 billion, representing changes of -8.7% and -0.15%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Pfizer. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.05% decrease. At present, Pfizer boasts a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Pfizer has a Forward P/E ratio of 10.12 right now. This valuation marks a discount compared to its industry average Forward P/E of 17.54.
It's also important to note that PFE currently trades at a PEG ratio of 2.02. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 2.02.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 218, placing it within the bottom 12% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Pfizer (PFE) Stock Sinks As Market Gains: Here's Why
Pfizer (PFE - Free Report) ended the recent trading session at $29.45, demonstrating a -1.17% change from the preceding day's closing price. This move lagged the S&P 500's daily gain of 0.28%. Meanwhile, the Dow gained 0.19%, and the Nasdaq, a tech-heavy index, added 0.27%.
Prior to today's trading, shares of the drugmaker had gained 3.76% outpaced the Medical sector's gain of 2.43% and the S&P 500's loss of 0.2%.
Market participants will be closely following the financial results of Pfizer in its upcoming release. The company plans to announce its earnings on November 3, 2026. The company is predicted to post an EPS of $0.72, indicating a 17.24% decline compared to the equivalent quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $16.13 billion, down 3.14% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $2.94 per share and a revenue of $62.48 billion, representing changes of -8.7% and -0.15%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Pfizer. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.05% decrease. At present, Pfizer boasts a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Pfizer has a Forward P/E ratio of 10.12 right now. This valuation marks a discount compared to its industry average Forward P/E of 17.54.
It's also important to note that PFE currently trades at a PEG ratio of 2.02. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 2.02.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 218, placing it within the bottom 12% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.